ClinicalTrials.gg
CompletedNCT06058390Updated Jul 18, 2025Results posted

A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants

A Phase 1 interventional study of Bepirovirsen in Hepatitis B, sponsored by GlaxoSmithKline. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-18.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing bepirovirsen in Hepatitis B — 3 open to participants now, 6 under way, none of them phase 3. bepirovirsen · Hepatitis B.

Enrollment
6th of 16
160 · median 103
Started
2023
the only one that year
Phase 1
5 of 16
1 open now
Registered
10th of 16
by date
Lead sponsor
15 of 16
GlaxoSmithKline

Among the 16 studies testing bepirovirsen in Hepatitis B, this one is the 6th largest by enrollment, is the only one that started in 2023, is one of 5 in phase 1, and was the 10th registered.

Hepatitis B

1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

3 of the 16 studies testing bepirovirsen in Hepatitis B are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About bepirovirsen

bepirovirsen: first FDA approval 2026 (HIBSAGO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing bepirovirsen in Hepatitis B, or all of them as a file.
02

Study summary

This is an open-label, randomized study to investigate subcutaneous (SC) bepirovirsen when delivered via SC injection from vial or Prefilled syringe fitted with a Safety syringe device (PFS SSD) in healthy adult participants. The aim of this study is to provide relative bioavailability data to support the transition from the vial presentation of bepirovirsen, to a ready-to-use liquid in a PFS SSD when both are given by a health care professional. The study will also assess self-administration using the PFS SDD, and the safety and tolerability of bepirovirsen.

03

Conditions studied

  • Hepatitis B

Keywords

  • Hepatitis B
  • Hepatitis
  • Viral
  • Human
  • Virus Diseases
  • Bepirovirsen
  • GSK3228836
  • 219239
  • Liver Diseases
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participants as determined by medical evaluation including medical history, physical examination, laboratory tests, (ECGs) and vital signs.
  • Capable of giving signed which includes compliance with the requirements and restrictions listed in the ICF and protocol.

Exclusion criteria

Exclusion Criteria:

  • Past or current medical conditions which, in the judgement of the investigator and Medical Monitor, could jeopardize the integrity of the data derived from that participant or the safety of the participant.
  • Abnormal blood pressure as determined by the investigator.
  • Positive virus (HBV), virus (HCV) or (HIV) test results.
  • Participants with signs or symptoms suggestive of Coronavirus disease 2019 (COVID-19) within 14 days of inpatient admission, or with a positive test for active COVID-19 infection before study start.
  • Past, current or intended use of over the counter or prescription medication [including herbal medications]
  • Current or prior use of creatine-containing supplements and intended use up to 50 days post-dosing.

Prior use of drugs within 3 months before dosing or interferon within 12 months before dosing.

  • Prior treatment with any oligonucleotide or small interfering ribonucleoside (RNA) siRNA within 12 months before dosing.
  • Loss of blood or blood products in excess of 500 millilitre (mL) within any 3-month period during the study.
  • Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.
  • Current enrolment or past participation in another study in which an investigational intervention (e.g., drug, vaccine, invasive device) was administered within 5-half-lives (if known) or twice the duration of biological effect (if known), whichever is longer, or within the last 90 days (if half-life and duration of biological effect are unknown), before the first dosing day in the current study.
  • Current enrolment or past participation in this clinical study.
  • Cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
  • Regular alcohol consumption of alcohol within 6 months prior to the study.
  • Regular use of known drugs of abuse, including Tetrahydrocannabinol (THC).
  • History of sensitivity to bepirovirsen or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor contraindicates their participation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Bepirovirsen Vial by HCP

    Participants will receive Bepirovirsen vial administered by Healthcare Professionals (HCP).

    Drug: Bepirovirsen

  • Experimental
    Bepirovirsen PFS SSD by HCP

    Participants will receive Bepirovirsen PFS SSD administered by HCP.

    Drug: Bepirovirsen

  • Experimental
    Bepirovirsen PFS SSD self-administered post-training

    Participants will receive Bepirovirsen PFS SSD self- administered with training by HCP.

    Drug: Bepirovirsen

  • Experimental
    Bepirovirsen PFS SSD self-administered without training

    Participants will receive Bepirovirsen PFS SSD self- administered with no training by HCP.

    Drug: Bepirovirsen

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) Following Administration of Bepirovirsen Using Vial and PFS by HCP

    Blood samples were collected at indicated timepoints for pharmacokinetic analysis of Bepirovirsen. Cmax calculation for this outcome measure is based on changes in model specifications and inclusion of different arms for respective outcome measures. Model includes Randomized Groups (Groups compared), injection site (arm, thigh and abdomen) as categorical covariates and log transformed Baseline weight as continuous covariate. The treatment is a factor in the model and position of a treatment as either test or reference would affect the Cmax values for a particular outcome measure due to differences in how the model accounts for variability and compares group for mean calculation. Pharmacokinetic (PK) Parameter Population included all participants in the PK concentration Population for whom valid and evaluable plasma PK parameters were derived.

    Time frame: Pre-dose (Day 1) and Post-dose (1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, 168 hours, 336 hours, 672 hours, 1008 hours and 1512 hours)

  2. Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC [0-Inf]) Following Administration of Bepirovirsen Using Vial and PFS by HCP

    Blood samples were collected at indicated timepoints for pharmacokinetic analysis of Bepirovirsen. Blood samples were collected at indicated timepoints for PK analysis of Bepirovirsen. AUC(0-inf) calculation for this outcome measure is based on changes in model specifications and inclusion of different arms for respective outcome measures. Model includes Randomized Groups (Groups compared), injection site (arm, thigh and abdomen) as categorical covariates and log transformed Baseline weight as continuous covariate. The treatment is a factor in the model and position of a treatment as either test or reference would affect the AUC(0-inf) values for a particular outcome measure due to differences in how the model accounts for variability and compares group for mean calculation.

    Time frame: Pre-dose (Day 1) and Post-dose (1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, 168 hours, 336 hours, 672 hours, 1008 hours and 1512 hours)

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) Following Administration of Bepirovirsen Using PFS SSD by HCP and PFS SSD Self-administered Post-training

    Blood samples were collected at indicated timepoints for pharmacokinetic analysis of Bepirovirsen. Cmax calculation for this outcome measure is based on changes in model specifications and inclusion of different arms for respective outcome measures. Model includes Randomized Groups (Groups compared), injection site (arm, thigh and abdomen) as categorical covariates and log transformed Baseline weight as continuous covariate. The treatment is a factor in the model and position of a treatment as either test or reference would affect the Cmax values for a particular outcome measure due to differences in how the model accounts for variability and compares group for mean calculation.

    Time frame: Pre-dose (Day 1) and Post-dose (1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, 168 hours, 336 hours, 672 hours, 1008 hours and 1512 hours)

  2. AUC(0-inf) Following Administration of Bepirovirsen Using PFS SSD by HCP and PFS SSD Self-administered Post-training

    Blood samples were collected at indicated timepoints for pharmacokinetic analysis of Bepirovirsen. Blood samples were collected at indicated timepoints for PK analysis of Bepirovirsen. AUC(0-inf) calculation for this outcome measure is based on changes in model specifications and inclusion of different arms for respective outcome measures. Model includes Randomized Groups (Groups compared), injection site (arm, thigh and abdomen) as categorical covariates and log transformed Baseline weight as continuous covariate. The treatment is a factor in the model and position of a treatment as either test or reference would affect the AUC(0-inf) values for a particular outcome measure due to differences in how the model accounts for variability and compares group for mean calculation.

    Time frame: Pre-dose (Day 1) and Post-dose (1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, 168 hours, 336 hours, 672 hours, 1008 hours and 1512 hours)

  3. Maximum Observed Plasma Concentration (Cmax) Following Administration of Bepirovirsen Using PFS SSD by HCP and PFS SSD Self-administered Without Training

    Blood samples were collected at indicated timepoints for pharmacokinetic analysis of Bepirovirsen. Cmax calculation for this outcome measure is based on changes in model specifications and inclusion of different arms for respective outcome measures. Model includes Randomized Groups (Groups compared), injection site (arm, thigh and abdomen) as categorical covariates and log transformed Baseline weight as continuous covariate. The treatment is a factor in the model and position of a treatment as either test or reference would affect the Cmax values for a particular outcome measure due to differences in how the model accounts for variability and compares group for mean calculation.

    Time frame: Pre-dose (Day 1) and Post-dose (1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, 168 hours, 336 hours, 672 hours, 1008 hours and 1512 hours)

  4. AUC(0-Inf) Following Administration of Bepirovirsen Using PFS SSD by HCP and PFS SSD Self-administered Without Training

    Blood samples were collected at indicated timepoints for pharmacokinetic analysis of Bepirovirsen. Blood samples were collected at indicated timepoints for PK analysis of Bepirovirsen. AUC(0-inf) calculation for this outcome measure is based on changes in model specifications and inclusion of different arms for respective outcome measures. Model includes Randomized Groups (Groups compared), injection site (arm, thigh and abdomen) as categorical covariates and log transformed Baseline weight as continuous covariate. The treatment is a factor in the model and position of a treatment as either test or reference would affect the AUC(0-inf) values for a particular outcome measure due to differences in how the model accounts for variability and compares group for mean calculation.

    Time frame: Pre-dose (Day 1) and Post-dose (1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, 168 hours, 336 hours, 672 hours, 1008 hours and 1512 hours)

07

Results

Posted Jul 18, 2025

Participant flow

Participant flow — Overall Study
MilestoneBepirovirsen 300 mg Vial by HCPBepirovirsen 300 mg PFS SSD by HCPBepirovirsen 300 mg PFS SSD Self-administered Post-trainingBepirovirsen 300 mg PFS SSD Self-administered Without Training
Started46493233
Safety population46493232
Completed46493030
Not completed0023
Withdrew: Lost to follow-up0021
Withdrew: Physician decision0001
Withdrew: Participants did not receive any study intervention0001

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) Following Administration of Bepirovirsen Using Vial and PFS by HCP

Blood samples were collected at indicated timepoints for pharmacokinetic analysis of Bepirovirsen. Cmax calculation for this outcome measure is based on changes in model specifications and inclusion of different arms for respective outcome measures. Model includes Randomized Groups (Groups compared), injection site (arm, thigh and abdomen) as categorical covariates and log transformed Baseline weight as continuous covariate. The treatment is a factor in the model and position of a treatment as either test or reference would affect the Cmax values for a particular outcome measure due to differences in how the model accounts for variability and compares group for mean calculation. Pharmacokinetic (PK) Parameter Population included all participants in the PK concentration Population for whom valid and evaluable plasma PK parameters were derived.

Time frame:
Pre-dose (Day 1) and Post-dose (1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, 168 hours, 336 hours, 672 hours, 1008 hours and 1512 hours)
Reported as:
Geometric mean · Nanograms per milliliters (ng/mL)
Maximum Observed Plasma Concentration (Cmax) Following Administration of Bepirovirsen Using Vial and PFS by HCP
Nanograms per milliliters (ng/mL)Bepirovirsen 300 mg Vial by HCPBepirovirsen 300 mg PFS SSD by HCP
Maximum Observed Plasma Concentration (Cmax) Following Administration of Bepirovirsen Using Vial and PFS by HCP9954.89 ± 0.04910163.74 ± 0.048
Statistical analysis
  • Bepirovirsen 300 mg Vial by HCP vs Bepirovirsen 300 mg PFS SSD by HCP · Geometric mean ratio: 1.02 · 90% CI 0.91 to 1.14Geometric mean is adjusted for covariates: randomized groups (Arms 1 and 2 of this endpoint), injection site (arm, thigh and abdomen) as categorical covariates and log transformed Baseline weight as continuous covariate.
PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC [0-Inf]) Following Administration of Bepirovirsen Using Vial and PFS by HCP

Blood samples were collected at indicated timepoints for pharmacokinetic analysis of Bepirovirsen. Blood samples were collected at indicated timepoints for PK analysis of Bepirovirsen. AUC(0-inf) calculation for this outcome measure is based on changes in model specifications and inclusion of different arms for respective outcome measures. Model includes Randomized Groups (Groups compared), injection site (arm, thigh and abdomen) as categorical covariates and log transformed Baseline weight as continuous covariate. The treatment is a factor in the model and position of a treatment as either test or reference would affect the AUC(0-inf) values for a particular outcome measure due to differences in how the model accounts for variability and compares group for mean calculation.

Time frame:
Pre-dose (Day 1) and Post-dose (1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, 168 hours, 336 hours, 672 hours, 1008 hours and 1512 hours)
Reported as:
Geometric mean · Hours*nanogram per milliliter (h*ng/mL)
Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC [0-Inf]) Following Administration of Bepirovirsen Using Vial and PFS by HCP
Hours*nanogram per milliliter (h*ng/mL)Bepirovirsen 300 mg Vial by HCPBepirovirsen 300 mg PFS SSD by HCP
Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC [0-Inf]) Following Administration of Bepirovirsen Using Vial and PFS by HCP112495.66 ± 0.039118622.59 ± 0.038
Statistical analysis
  • Bepirovirsen 300 mg Vial by HCP vs Bepirovirsen 300 mg PFS SSD by HCP · Geometric mean ratio: 1.05 · 90% CI 0.96 to 1.15Geometric mean is adjusted for covariates: randomized groups (Arms 1 and 2 of this endpoint), injection site (arm, thigh and abdomen) as categorical covariates and log transformed Baseline weight as continuous covariate.
SecondaryMaximum Observed Plasma Concentration (Cmax) Following Administration of Bepirovirsen Using PFS SSD by HCP and PFS SSD Self-administered Post-training

Blood samples were collected at indicated timepoints for pharmacokinetic analysis of Bepirovirsen. Cmax calculation for this outcome measure is based on changes in model specifications and inclusion of different arms for respective outcome measures. Model includes Randomized Groups (Groups compared), injection site (arm, thigh and abdomen) as categorical covariates and log transformed Baseline weight as continuous covariate. The treatment is a factor in the model and position of a treatment as either test or reference would affect the Cmax values for a particular outcome measure due to differences in how the model accounts for variability and compares group for mean calculation.

Time frame:
Pre-dose (Day 1) and Post-dose (1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, 168 hours, 336 hours, 672 hours, 1008 hours and 1512 hours)
Reported as:
Geometric mean · Nanograms per milliliters
Maximum Observed Plasma Concentration (Cmax) Following Administration of Bepirovirsen Using PFS SSD by HCP and PFS SSD Self-administered Post-training
Nanograms per millilitersBepirovirsen 300 mg PFS SSD by HCPBepirovirsen 300 mg PFS SSD Self-administered Post-training
Maximum Observed Plasma Concentration (Cmax) Following Administration of Bepirovirsen Using PFS SSD by HCP and PFS SSD Self-administered Post-training10225.39 ± 0.05010421.21 ± 0.067
Statistical analysis
  • Bepirovirsen 300 mg PFS SSD by HCP vs Bepirovirsen 300 mg PFS SSD Self-administered Post-training · Geometric mean ratio: 1.02 · 90% CI 0.88 to 1.18Geometric mean is adjusted for covariates: randomized groups (Arms 1 and 2 of this endpoint), injection site (arm, thigh and abdomen) as categorical covariates and log transformed baseline weight as continuous covariate.
SecondaryAUC(0-inf) Following Administration of Bepirovirsen Using PFS SSD by HCP and PFS SSD Self-administered Post-training

Blood samples were collected at indicated timepoints for pharmacokinetic analysis of Bepirovirsen. Blood samples were collected at indicated timepoints for PK analysis of Bepirovirsen. AUC(0-inf) calculation for this outcome measure is based on changes in model specifications and inclusion of different arms for respective outcome measures. Model includes Randomized Groups (Groups compared), injection site (arm, thigh and abdomen) as categorical covariates and log transformed Baseline weight as continuous covariate. The treatment is a factor in the model and position of a treatment as either test or reference would affect the AUC(0-inf) values for a particular outcome measure due to differences in how the model accounts for variability and compares group for mean calculation.

Time frame:
Pre-dose (Day 1) and Post-dose (1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, 168 hours, 336 hours, 672 hours, 1008 hours and 1512 hours)
Reported as:
Geometric mean · Hours*nanograms per milliliters
AUC(0-inf) Following Administration of Bepirovirsen Using PFS SSD by HCP and PFS SSD Self-administered Post-training
Hours*nanograms per millilitersBepirovirsen 300 mg PFS SSD by HCPBepirovirsen 300 mg PFS SSD Self-administered Post-training
AUC(0-inf) Following Administration of Bepirovirsen Using PFS SSD by HCP and PFS SSD Self-administered Post-training120034.02 ± 0.038117805.29 ± 0.050
Statistical analysis
  • Bepirovirsen 300 mg PFS SSD by HCP vs Bepirovirsen 300 mg PFS SSD Self-administered Post-training · Geometric mean ratio: 0.98 · 90% CI 0.88 to 1.09Geometric mean is adjusted for covariates: randomized groups (Arms 1 and 2 of this endpoint), injection site (arm, thigh and abdomen) as categorical covariates and log transformed Baseline weight as continuous covariate.
SecondaryMaximum Observed Plasma Concentration (Cmax) Following Administration of Bepirovirsen Using PFS SSD by HCP and PFS SSD Self-administered Without Training

Blood samples were collected at indicated timepoints for pharmacokinetic analysis of Bepirovirsen. Cmax calculation for this outcome measure is based on changes in model specifications and inclusion of different arms for respective outcome measures. Model includes Randomized Groups (Groups compared), injection site (arm, thigh and abdomen) as categorical covariates and log transformed Baseline weight as continuous covariate. The treatment is a factor in the model and position of a treatment as either test or reference would affect the Cmax values for a particular outcome measure due to differences in how the model accounts for variability and compares group for mean calculation.

Time frame:
Pre-dose (Day 1) and Post-dose (1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, 168 hours, 336 hours, 672 hours, 1008 hours and 1512 hours)
Reported as:
Geometric mean · Nanograms per milliliters
Maximum Observed Plasma Concentration (Cmax) Following Administration of Bepirovirsen Using PFS SSD by HCP and PFS SSD Self-administered Without Training
Nanograms per millilitersBepirovirsen 300 mg PFS SSD by HCPBepirovirsen 300 mg PFS SSD Self-administered Without Training
Maximum Observed Plasma Concentration (Cmax) Following Administration of Bepirovirsen Using PFS SSD by HCP and PFS SSD Self-administered Without Training10007.69 ± 0.0469896.63 ± 0.061
Statistical analysis
  • Bepirovirsen 300 mg PFS SSD by HCP vs Bepirovirsen 300 mg PFS SSD Self-administered Without Training · Geometric mean ratio: 0.99 · 90% CI 0.87 to 1.13Geometric mean is adjusted for covariates: randomized groups (Arms 1 and 2 of this endpoint), injection site (arm, thigh and abdomen) as categorical covariates and log transformed Baseline weight as continuous covariate.
SecondaryAUC(0-Inf) Following Administration of Bepirovirsen Using PFS SSD by HCP and PFS SSD Self-administered Without Training

Blood samples were collected at indicated timepoints for pharmacokinetic analysis of Bepirovirsen. Blood samples were collected at indicated timepoints for PK analysis of Bepirovirsen. AUC(0-inf) calculation for this outcome measure is based on changes in model specifications and inclusion of different arms for respective outcome measures. Model includes Randomized Groups (Groups compared), injection site (arm, thigh and abdomen) as categorical covariates and log transformed Baseline weight as continuous covariate. The treatment is a factor in the model and position of a treatment as either test or reference would affect the AUC(0-inf) values for a particular outcome measure due to differences in how the model accounts for variability and compares group for mean calculation.

Time frame:
Pre-dose (Day 1) and Post-dose (1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, 168 hours, 336 hours, 672 hours, 1008 hours and 1512 hours)
Reported as:
Geometric mean · Hours*nanograms per milliliters
AUC(0-Inf) Following Administration of Bepirovirsen Using PFS SSD by HCP and PFS SSD Self-administered Without Training
Hours*nanograms per millilitersBepirovirsen 300 mg PFS SSD by HCPBepirovirsen 300 mg PFS SSD Self-administered Without Training
AUC(0-Inf) Following Administration of Bepirovirsen Using PFS SSD by HCP and PFS SSD Self-administered Without Training117938.68 ± 0.037114492.19 ± 0.049
Statistical analysis
  • Bepirovirsen 300 mg PFS SSD by HCP vs Bepirovirsen 300 mg PFS SSD Self-administered Without Training · Geometric mean ratio: 0.97 · 90% CI 0.87 to 1.08Geometric mean is adjusted for covariates: randomized groups (Arms 1 and 2 of this endpoint), injection site (arm, thigh and abdomen) as categorical covariates and log transformed Baseline weight as continuous covariate.

Adverse events

Collected over All-cause mortality, serious adverse events (SAEs) and non-serious adverse events (Non-SAEs) were collected up to Day 64. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bepirovirsen 300 mg Vial by HCP0/46 (0%)0/46 (0%)45/46 (97.8%)
Bepirovirsen 300 mg PFS SSD by HCP0/49 (0%)0/49 (0%)43/49 (87.8%)
Bepirovirsen 300 mg PFS SSD Self-administered Post-training0/32 (0%)0/32 (0%)32/32 (100%)
Bepirovirsen 300 mg PFS SSD Self-administered Without Training0/32 (0%)0/32 (0%)30/32 (93.8%)
Most frequent other events
Showing 10 of 92
Most frequent other events
EventBepirovirsen 300 mg Vial by HCPBepirovirsen 300 mg PFS SSD by HCPBepirovirsen 300 mg PFS SSD Self-administered Post-trainingBepirovirsen 300 mg PFS SSD Self-administered Without Training
Injection site erythemaGeneral disorders35/4637/4930/3230/32
Injection site swellingGeneral disorders21/4624/4914/3219/32
Injection site painGeneral disorders23/4622/4910/3212/32
Injection site pruritusGeneral disorders8/4611/499/3213/32
HeadacheNervous system disorders12/465/495/327/32
Injection site discolourationGeneral disorders7/465/496/325/32
Injection site pallorGeneral disorders6/463/495/323/32
Injection site bruisingGeneral disorders2/463/494/321/32
Injection site haemorrhageGeneral disorders5/462/493/321/32
MyalgiaMusculoskeletal and connective tissue disorders5/461/491/321/32

Baseline characteristics

Baseline characteristics were reported for the Safety Population which included participants who received study intervention.

Age, Continuous
Age, Continuous(YEARS)Bepirovirsen 300 mg Vial by HCPBepirovirsen 300 mg PFS SSD by HCPBepirovirsen 300 mg PFS SSD Self-administered Post-trainingBepirovirsen 300 mg PFS SSD Self-administered Without TrainingTotal
Mean35.7 ± 9.0936.5 ± 9.5736.6 ± 9.3537.5 ± 9.7436.5 ± 9.35
Sex: Female, Male
Sex: Female, Male(Participants)Bepirovirsen 300 mg Vial by HCPBepirovirsen 300 mg PFS SSD by HCPBepirovirsen 300 mg PFS SSD Self-administered Post-trainingBepirovirsen 300 mg PFS SSD Self-administered Without TrainingTotal
Female2625151682
Male2024171677
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bepirovirsen 300 mg Vial by HCPBepirovirsen 300 mg PFS SSD by HCPBepirovirsen 300 mg PFS SSD Self-administered Post-trainingBepirovirsen 300 mg PFS SSD Self-administered Without TrainingTotal
WHITE2520131876
All Other Races2129191483
08

Study locations

2 sites
  • GSK Investigational Site
    Las Vegas, Nevada 89113, United States
  • GSK Investigational Site
    Austin, Texas 78744, United States
09

References and documents

Publications

  • Youssef AS, Shah P, Hu M, Plein H, Roy A, Sharma R, Mole S, Blazejczyk M, Cross W, Spears B, Pak S, Kaur R, Elston R, Theodore D, Hezareh M, Nader A. A Phase 1, Randomized, Open-Label, Parallel Group Study to Evaluate the Relative Bioavailability and Safety of Subcutaneous Bepirovirsen when Delivered from a Vial or Prefilled Syringe Fitted with a Safety Syringe Device in Healthy Adult Participants. Clin Pharmacol Drug Dev. 2026 Feb;15(2):e1615. doi: 10.1002/cpdd.1615. Epub 2025 Oct 14. PubMed 41085094 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in May 2024, 6 months.

Results were first posted in Jul 2025, 1 year 2 months after primary completion.

Of 49 industry-sponsored phase 1 interventional studies under Hepatitis B, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 6 months is below that.

Counting every sponsor, half of 58 studies reached it within 14 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2023
First posted
Sep 28, 2023
StartActual
Oct 4, 2023
Primary completionActual
May 3, 2024
CompletionActual
May 3, 2024
Results first posted
Jul 18, 2025
Last update
Jul 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06058390
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 28, 2023
Start date
Oct 4, 2023
Primary completion
May 3, 2024
Completion
May 3, 2024
Results posted
Jul 18, 2025
Last update
Jul 18, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bepirovirsen

Start the discussion